UNSPSC 41131509: Automated hematocrit instrument

In this classification, an automated hematocrit instrument is a fully automated or semi-automated device which may or may not be part of a larger system. This device measures the packed red cell volume of a blood sample to distinguish normal from abnormal states, such as anemia and erythrocytosis (an increase in the number of red cells). US FDA regulates Automated hematocrit instrument under 21 CFR 864.5600 and under FDA product code GKF.

UNSPSC 41131509 Automated hematocrit instrument is a Commodity code under which state and local health agencies procure specialized laboratory analyzers and proficiency testing materials for blood analysis screening programs. The Texas Health and Human Services Commission and Department of State Health Services issued an Invitation for Bids in May 2026 for a D-10 Hemoglobin Testing System with Rack Loader — an ion-exchange HPLC analyzer for HbA1c and fetal screening applications — to replace end-of-life equipment at the South Texas Lab in Harlingen. State and local buyers under this code are predominantly state health departments and university research institutions; the University of Wisconsin-Madison also solicited custom-made Hematology/Whole Blood Chemistry Proficiency Testing Samples under a competitive bid in April 2026, reflecting demand across academic and public health laboratory networks for both capital equipment and consumable quality-assurance materials.

Recent activity concentrates in Texas and Wisconsin. The Texas HHSC D-10 system procurement, posted May 1, 2026, with bids due May 18, 2026, was firm-fixed-price with no substitutions permitted and an anticipated award date of May 19, 2026; historical spending for similar goods ranged $45,050 to $80,000 in fiscal year 2025. The University of Wisconsin ShopUW+ competitive bid for hematology proficiency testing samples, posted April 3, 2026, closed May 5, 2026, with no disclosed budget or incumbent vendor. Both Texas HHSC opportunities — the May 2026 D-10 system IFB and an earlier March 2026 IFB for PerkinElmer ICP-MS consumables and supplies for pediatric blood lead screening — show the agency executing multiple laboratory procurement cycles to support clinical and screening operations, though award values and volumes are not guaranteed and all contracts are contingent on appropriations and fund availability.